ID: ALA387573

Max Phase: Preclinical

Molecular Formula: C34H46N10O3

Molecular Weight: 642.81

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)NCc1ccccc1

Standard InChI:  InChI=1S/C34H46N10O3/c35-27(13-7-19-40-33(36)37)30(45)44-29(21-23-15-17-26(18-16-23)25-11-5-2-6-12-25)32(47)43-28(14-8-20-41-34(38)39)31(46)42-22-24-9-3-1-4-10-24/h1-6,9-12,15-18,27-29H,7-8,13-14,19-22,35H2,(H,42,46)(H,43,47)(H,44,45)(H4,36,37,40)(H4,38,39,41)/t27-,28-,29-/m0/s1

Standard InChI Key:  IIUQVWAODMBQQA-AWCRTANDSA-N

Associated Targets(non-human)

Staphylococcus aureus 210822 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Escherichia coli 133304 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Liver 8163 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Stomach 551 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Duodenum 21 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 642.81Molecular Weight (Monoisotopic): 642.3754AlogP: 1.04#Rotatable Bonds: 18
Polar Surface Area: 237.12Molecular Species: BASEHBA: 6HBD: 10
#RO5 Violations: 2HBA (Lipinski): 13HBD (Lipinski): 13#RO5 Violations (Lipinski): 3
CX Acidic pKa: 12.31CX Basic pKa: 11.87CX LogP: 0.39CX LogD: -4.37
Aromatic Rings: 3Heavy Atoms: 47QED Weighted: 0.05Np Likeness Score: -0.07

References

1. Svenson J, Brandsdal BO, Stensen W, Svendsen JS..  (2007)  Albumin binding of short cationic antimicrobial micropeptides and its influence on the in vitro bactericidal effect.,  50  (14): [PMID:17569519] [10.1021/jm0703542]
2. Karstad R, Isaksen G, Brandsdal BO, Svendsen JS, Svenson J..  (2010)  Unnatural amino acid side chains as S1, S1', and S2' probes yield cationic antimicrobial peptides with stability toward chymotryptic degradation.,  53  (15): [PMID:20608742] [10.1021/jm1006337]
3. Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J..  (2011)  In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides.,  54  (7): [PMID:21401113] [10.1021/jm1015704]
4. Karstad R, Isaksen G, Wynendaele E, Guttormsen Y, De Spiegeleer B, Brandsdal BO, Svendsen JS, Svenson J..  (2012)  Targeting the S1 and S3 subsite of trypsin with unnatural cationic amino acids generates antimicrobial peptides with potential for oral administration.,  55  (14): [PMID:22720778] [10.1021/jm3002058]

Source